| PRODUCTSSERVICESCOMPANYCONTACTFAQ |
|
Description: anticancer drug in Phase III clinical trial (7/2003); spelled both ways in the article
Also Known As:| 1. | Tang, Wei: 1 article (11/2006) |
| 2. | Yuan, Yun-Xia: 1 article (11/2006) |
| 3. | Chen, Ming-Hui: 1 article (11/2006) |
| 4. | Makuuchi, Masatoshi: 1 article (11/2006) |
| 5. | Qu, Xian-Jun: 1 article (11/2006) |
| 6. | Zhou, Yong: 1 article (11/2006) |
| 7. | Wang, Ruo-Han: 1 article (11/2006) |
| 8. | Liu, Jian: 1 article (11/2006) |
| 9. | Xu, Wen-Fang: 1 article (11/2006) |
| 10. | Cui, Shu-Xiang: 1 article (11/2006) |
| 1. | Carcinoma (Carcinomatosis)
11/14/2006
- "AIM: To evaluate the growth inhibition efficacy of atofluding derivative N3-o-toluyl-fluorouracil (TFU) on human gastric carcinoma cell lines SGC-7901 and MKN-45. "
11/14/2006 - "Inhibition of human gastric carcinoma cell growth by atofluding derivative N3-o-toluyl-fluorouracil." Order ALL the reference details at left... |
| 1. | N3-o-toluyl-fluorouracil
|
CureHunter Patient-Physician Summary Reports collect in one document all the
medications ever reported in the US National Library of Medicine—1949 to the present—to
be effective against your target disease.
CureHunter research summary reports will vary in length from 25 to 250 pages.
Analytic charts allow you and your physicians to see at a glance your
medication options—including new, promising, off-label and experimental
all rated for clinical efficacy.
| Price: | $24.00
& Delivery via
PDF download
updates for 1 year |
| Price: | $490.00
access via web interface 1 year subscription |
| Price: | $45.00
access via "curehunter.com/m" 1 year subscription |